Are you over 18 and want to see adult content?
More Annotations
A complete backup of lutheransforlife.org
Are you over 18 and want to see adult content?
A complete backup of burnerswithoutborders.org
Are you over 18 and want to see adult content?
A complete backup of armagetronad.net
Are you over 18 and want to see adult content?
A complete backup of xn--e1aaqdchbhj1a9i.xn--p1ai
Are you over 18 and want to see adult content?
A complete backup of myboracayguide.com
Are you over 18 and want to see adult content?
A complete backup of frenchmanscreek.com
Are you over 18 and want to see adult content?
A complete backup of kingsportsmouth.co.uk
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of animefeet.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of fatesbattery.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of blackmores-musikzimmer.de
Are you over 18 and want to see adult content?
A complete backup of fig-and-flower.myshopify.com
Are you over 18 and want to see adult content?
A complete backup of centrealliance.org.au
Are you over 18 and want to see adult content?
A complete backup of indiajoining.com
Are you over 18 and want to see adult content?
Text
financial analysts.
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. DIRECTOR/EXECUTIVE DIRECTOR, PHARMACOVIGILANCE/DRUG SAFETY The Director/Executive Director, Pharmacovigilance/Drug Safety will require in-depth subject matter expertise, strong operational strategic thinking and leadership skills to effectively manage safety and global pharmacovigilance, including both developing a departmental strategy as well as managing the-day to day operations. The role oversees pharmacovigilance for RedHill’s marketed drugs RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHEUMATOID ARTHRITIS 20 May, 2021 RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021 ; 9 April, 2021 RedHill Biopharma’s Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue ; 25 March, 2021 RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN PATIENT ASSISTANCE PROGRAM APPLICATION uestions? Call 1-844-734-5727 MondayFriday, 9 AM to 6 PM ET or visit www.redhillbio.com/patientassistance Patient Assistance Program Application Page 6 of 9 Patient NEW POTENTIAL THERAPEUTIC APPLICATIONS OF WX-UK1, AS A New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases Emil Oldenburg1, Christine R. Schar1, Eva L. Lange1, Terry F. Plasse2, Danielle T Abramson2, Eric M. Towler2, Mark Levitt2,3, Reza Fathi2, and Jan K Jensen1 1Institute of Molecular Biology and Genetics, Aarhus University, Gustav Wieds vej 10, 8000 Aarhus C, Denmark. HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 PATIENT ASSISTANCE PROGRAM 7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. DIRECTOR/EXECUTIVE DIRECTOR, PHARMACOVIGILANCE/DRUG SAFETY The Director/Executive Director, Pharmacovigilance/Drug Safety will require in-depth subject matter expertise, strong operational strategic thinking and leadership skills to effectively manage safety and global pharmacovigilance, including both developing a departmental strategy as well as managing the-day to day operations. The role oversees pharmacovigilance for RedHill’s marketed drugs RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHEUMATOID ARTHRITIS 20 May, 2021 RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021 ; 9 April, 2021 RedHill Biopharma’s Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue ; 25 March, 2021 RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN PATIENT ASSISTANCE PROGRAM APPLICATION uestions? Call 1-844-734-5727 MondayFriday, 9 AM to 6 PM ET or visit www.redhillbio.com/patientassistance Patient Assistance Program Application Page 6 of 9 Patient NEW POTENTIAL THERAPEUTIC APPLICATIONS OF WX-UK1, AS A New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases Emil Oldenburg1, Christine R. Schar1, Eva L. Lange1, Terry F. Plasse2, Danielle T Abramson2, Eric M. Towler2, Mark Levitt2,3, Reza Fathi2, and Jan K Jensen1 1Institute of Molecular Biology and Genetics, Aarhus University, Gustav Wieds vej 10, 8000 Aarhus C, Denmark.PRODUCTS & PIPELINE
7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19OPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19.OPAGANIB - COVID-19
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
MULTIPLE SCLEROSIS
7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
2020 | NEWS | REDHILL 9 June, 2021 RedHill Biopharma to Present at the BIO Digital International Convention ; 7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational HighlightsCROHN'S DISEASE
RedHill Presentation - International Research Symposium for Game Changing Concepts in Crohn’s Medicine (RHB-104 Phase III Program) RedHill Article (RHB-104) - Crohn's & Colitis Canada 2015 Gala Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Elaboration on Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Doctors have potentially found NATIONAL ACCOUNT EXECUTIVE (NAE) The National Account Executive (NAE) is responsible for representing RedHill Biopharma products and co-promote products for national, regional, and federal accounts.This position covers large geographical areas. The NAE understands how to develop key customers and customer relationships within the Managed Care market place and can facilitate growth of RedHill Biopharma products. REDHILL BIOPHARMA ACQUIRES RIGHTS TO MOVANTIK® FROM 25 February, 2020. RedHill to promote Movantik ® in the U.S. upon closing . Movantik ® generated U.S. net sales of $96 million in 2019. Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million non-dilutive financing announced today TEL-AVIV, Israel and RALEIGH, N.C., February 25, 2020-- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the NEW POTENTIAL THERAPEUTIC APPLICATIONS OF WX-UK1, AS A New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases Emil Oldenburg1, Christine R. Schar1, Eva L. Lange1, Terry F. Plasse2, Danielle T Abramson2, Eric M. Towler2, Mark Levitt2,3, Reza Fathi2, and Jan K Jensen1 1Institute of Molecular Biology and Genetics, Aarhus University, Gustav Wieds vej 10, 8000 Aarhus C, Denmark. HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19PRODUCTS & PIPELINE
Commercial Products. RedHill has assembled an experienced specialty gastrointestinal-focused commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes several gastrointestinal specialty products in the U.S.: Talicia ® (omeprazole magnesium, amoxicillin and rifabutin PATIENT ASSISTANCE PROGRAM The PAP is for U.S. citizens that live in one of the 50 states, the District of Columbia, or Puerto Rico and meet all eligibility criteria. The PAP does not constitute health insurance. All RedHill medications are currently available through the PAP. You and your U.S. licensed prescriber must complete the RedHill Biopharma PAPapplication.
OPAGANIB - COVID-19
There is an urgent need for effective new therapies to help decrease the severity and duration of respiratory symptoms due to SARS-CoV-2 infection (the cause of COVID-19). RedHill is working to develop opaganib (Yeliva, ACB294640) 1 for COVID-19. Opaganib is a novel, orally administered, sphingosine kinase-2 (SK2) selective inhibitorwith a
2021 | NEWS | REDHILL 7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
OPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not require CONTACT | REDHILLSEE MORE ON REDHILLBIO.COM RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RedHill initiated a Phase 3 study to evaluate the efficacy and safety of RHB-204 as a first-line treatment of pulmonary NTM disease caused by Mycobacterium avium complex (MAC HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19PRODUCTS & PIPELINE
Commercial Products. RedHill has assembled an experienced specialty gastrointestinal-focused commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes several gastrointestinal specialty products in the U.S.: Talicia ® (omeprazole magnesium, amoxicillin and rifabutin PATIENT ASSISTANCE PROGRAM The PAP is for U.S. citizens that live in one of the 50 states, the District of Columbia, or Puerto Rico and meet all eligibility criteria. The PAP does not constitute health insurance. All RedHill medications are currently available through the PAP. You and your U.S. licensed prescriber must complete the RedHill Biopharma PAPapplication.
OPAGANIB - COVID-19
There is an urgent need for effective new therapies to help decrease the severity and duration of respiratory symptoms due to SARS-CoV-2 infection (the cause of COVID-19). RedHill is working to develop opaganib (Yeliva, ACB294640) 1 for COVID-19. Opaganib is a novel, orally administered, sphingosine kinase-2 (SK2) selective inhibitorwith a
2021 | NEWS | REDHILL 7 June, 2021 RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study ; 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
OPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not require CONTACT | REDHILLSEE MORE ON REDHILLBIO.COM RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RedHill initiated a Phase 3 study to evaluate the efficacy and safety of RHB-204 as a first-line treatment of pulmonary NTM disease caused by Mycobacterium avium complex (MACPRODUCTS & PIPELINE
Commercial Products. RedHill has assembled an experienced specialty gastrointestinal-focused commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes several gastrointestinal specialty products in the U.S.: Talicia ® (omeprazole magnesium, amoxicillin and rifabutinCONTACT | REDHILL
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites").CROHN'S DISEASE
Crohn's disease. RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. Crohn’s disease is an inflammatory disease of the gastrointestinal system with significant unmet needs. The inflammation caused byCrohn's
2020 | NEWS | REDHILL RedHill Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy. 27 August, 2020. Download file 236.9 Kb |. RHB-104 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-104. RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium subspeciesparatuberculosis
RHB-102 (BEKINDA®)
RHB-102 (Bekinda ®) is a proprietary, oral, extended-release (24 hours), once-daily pill formulation of the antiemetic drug ondansetron, in development for multiple gastrointestinal indications.. Ondansetron is a 5-HT3 (serotonin) receptor antagonist which is marketed under various trade names including GSK’s Zofran . 5-HT3 receptor antagonists are considered the most effective andMULTIPLE SCLEROSIS
Multiple Sclerosis. RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. Multiple Sclerosis is an inflammatory, demyelinating, and neurodegenerative disease of the central nervoussystem of uncertain
NEW POTENTIAL THERAPEUTIC APPLICATIONS OF WX-UK1, AS A New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases Emil Oldenburg1, Christine R. Schar1, Eva L. Lange1, Terry F. Plasse2, Danielle T Abramson2, Eric M. Towler2, Mark Levitt2,3, Reza Fathi2, and Jan K Jensen1 1Institute of Molecular Biology and Genetics, Aarhus University, Gustav Wieds vej 10, 8000 Aarhus C, Denmark. AEMCOLO® | COMMERCIAL PRODUCTS | PRODUCTS | REDHILL Aemcolo ® (rifamycin) is an orally administered, delayed release, minimally absorbed antibiotic approved for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia coli ( E.coli ) in adults. Aemcolo ® is the first antibiotic engineered with Cosmo Pharmaceuticals’ Multi Matrix Technology (MMX).
ABOUT REDHILL
About RedHill. RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes three gastrointestinal products in the U.S.: Talicia ® (omeprazole magnesium, amoxicillin and rifabutin) Opaganib (Yeliva ® , ABC294640) - An orally-administered,first
HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PRODUCTS & PIPELINE
Commercial Products. RedHill has assembled an experienced specialty gastrointestinal-focused commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes several gastrointestinal specialty products in the U.S.: Talicia ® (omeprazole magnesium, amoxicillin and rifabutin PATIENT ASSISTANCE PROGRAM The PAP is for U.S. citizens that live in one of the 50 states, the District of Columbia, or Puerto Rico and meet all eligibility criteria. The PAP does not constitute health insurance. All RedHill medications are currently available through the PAP. You and your U.S. licensed prescriber must complete the RedHill Biopharma PAPapplication.
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB - COVID-19
There is an urgent need for effective new therapies to help decrease the severity and duration of respiratory symptoms due to SARS-CoV-2 infection (the cause of COVID-19). RedHill is working to develop opaganib (Yeliva, ACB294640) 1 for COVID-19. Opaganib is a novel, orally administered, sphingosine kinase-2 (SK2) selective inhibitorwith a
OPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RedHill initiated a Phase 3 study to evaluate the efficacy and safety of RHB-204 as a first-line treatment of pulmonary NTM disease caused by Mycobacterium avium complex (MAC DIRECTOR/EXECUTIVE DIRECTOR, PHARMACOVIGILANCE/DRUG SAFETY The Director/Executive Director, Pharmacovigilance/Drug Safety will require in-depth subject matter expertise, strong operational strategic thinking and leadership skills to effectively manage safety and global pharmacovigilance, including both developing a departmental strategy as well as managing the-day to day operations. The role oversees pharmacovigilance for RedHill’s marketed drugs PATIENT ASSISTANCE PROGRAM APPLICATION uestions? Call 1-844-734-5727 MondayFriday, 9 AM to 6 PM ET or visit www.redhillbio.com/patientassistance Patient Assistance Program Application Page 6 of 9 Patient NEW POTENTIAL THERAPEUTIC APPLICATIONS OF WX-UK1, AS A New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases Emil Oldenburg1, Christine R. Schar1, Eva L. Lange1, Terry F. Plasse2, Danielle T Abramson2, Eric M. Towler2, Mark Levitt2,3, Reza Fathi2, and Jan K Jensen1 1Institute of Molecular Biology and Genetics, Aarhus University, Gustav Wieds vej 10, 8000 Aarhus C, Denmark. HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PRODUCTS & PIPELINE
Commercial Products. RedHill has assembled an experienced specialty gastrointestinal-focused commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes several gastrointestinal specialty products in the U.S.: Talicia ® (omeprazole magnesium, amoxicillin and rifabutin PATIENT ASSISTANCE PROGRAM The PAP is for U.S. citizens that live in one of the 50 states, the District of Columbia, or Puerto Rico and meet all eligibility criteria. The PAP does not constitute health insurance. All RedHill medications are currently available through the PAP. You and your U.S. licensed prescriber must complete the RedHill Biopharma PAPapplication.
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB - COVID-19
There is an urgent need for effective new therapies to help decrease the severity and duration of respiratory symptoms due to SARS-CoV-2 infection (the cause of COVID-19). RedHill is working to develop opaganib (Yeliva, ACB294640) 1 for COVID-19. Opaganib is a novel, orally administered, sphingosine kinase-2 (SK2) selective inhibitorwith a
OPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RedHill initiated a Phase 3 study to evaluate the efficacy and safety of RHB-204 as a first-line treatment of pulmonary NTM disease caused by Mycobacterium avium complex (MAC DIRECTOR/EXECUTIVE DIRECTOR, PHARMACOVIGILANCE/DRUG SAFETY The Director/Executive Director, Pharmacovigilance/Drug Safety will require in-depth subject matter expertise, strong operational strategic thinking and leadership skills to effectively manage safety and global pharmacovigilance, including both developing a departmental strategy as well as managing the-day to day operations. The role oversees pharmacovigilance for RedHill’s marketed drugs PATIENT ASSISTANCE PROGRAM APPLICATION uestions? Call 1-844-734-5727 MondayFriday, 9 AM to 6 PM ET or visit www.redhillbio.com/patientassistance Patient Assistance Program Application Page 6 of 9 Patient NEW POTENTIAL THERAPEUTIC APPLICATIONS OF WX-UK1, AS A New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases Emil Oldenburg1, Christine R. Schar1, Eva L. Lange1, Terry F. Plasse2, Danielle T Abramson2, Eric M. Towler2, Mark Levitt2,3, Reza Fathi2, and Jan K Jensen1 1Institute of Molecular Biology and Genetics, Aarhus University, Gustav Wieds vej 10, 8000 Aarhus C, Denmark.PRODUCTS & PIPELINE
Commercial Products. RedHill has assembled an experienced specialty gastrointestinal-focused commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes several gastrointestinal specialty products in the U.S.: Talicia ® (omeprazole magnesium, amoxicillin and rifabutinOPAGANIB - COVID-19
There is an urgent need for effective new therapies to help decrease the severity and duration of respiratory symptoms due to SARS-CoV-2 infection (the cause of COVID-19). RedHill is working to develop opaganib (Yeliva, ACB294640) 1 for COVID-19. Opaganib is a novel, orally administered, sphingosine kinase-2 (SK2) selective inhibitorwith a
OPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. 2020 | NEWS | REDHILL RedHill Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy. 27 August, 2020. Download file 236.9 Kb |.PIPELINE OVERVIEW
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
MOVANTIK® | COMMERCIAL PRODUCTS | PRODUCTS | REDHILL MOVANTIK is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer. You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or www REDHILL BIOPHARMA COMPLETES ENROLLMENT OF ORAL OPAGANIB 1 Opaganib is an investigational new drug, not available for commercial distribution.. 2 Based on preliminary blinded blended data from 463 patients. The Company did not conduct a head-to-head comparison study in the same patient population. The theoretical comparison between the global Phase 2/3 study with opaganib and reported rates of mortality from large platform studies such asCROHN'S DISEASE
Crohn's disease. RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. Crohn’s disease is an inflammatory disease of the gastrointestinal system with significant unmet needs. The inflammation caused byCrohn's
REDHILL BIOPHARMA ACQUIRES RIGHTS TO MOVANTIK® FROM 25 February, 2020. RedHill to promote Movantik ® in the U.S. upon closing . Movantik ® generated U.S. net sales of $96 million in 2019. Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million non-dilutive financing announced today TEL-AVIV, Israel and RALEIGH, N.C., February 25, 2020-- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PRODUCTS & PIPELINE
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PATIENT ASSISTANCE PROGRAM 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
CAREERS - HOME
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILLRHB 104 APPROVALRHB 104 NEWSRHB 104 RESULTSRHB 104 STUDY RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. CONTACT | REDHILLSEE MORE ON REDHILLBIO.COMCROHN'S DISEASE
RedHill Presentation - International Research Symposium for Game Changing Concepts in Crohn’s Medicine (RHB-104 Phase III Program) RedHill Article (RHB-104) - Crohn's & Colitis Canada 2015 Gala Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Elaboration on Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Doctors have potentially found HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PRODUCTS & PIPELINE
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PATIENT ASSISTANCE PROGRAM 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
CAREERS - HOME
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILLRHB 104 APPROVALRHB 104 NEWSRHB 104 RESULTSRHB 104 STUDY RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. CONTACT | REDHILLSEE MORE ON REDHILLBIO.COMCROHN'S DISEASE
RedHill Presentation - International Research Symposium for Game Changing Concepts in Crohn’s Medicine (RHB-104 Phase III Program) RedHill Article (RHB-104) - Crohn's & Colitis Canada 2015 Gala Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Elaboration on Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Doctors have potentially foundABOUT REDHILL
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
2020 | NEWS | REDHILL 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PIPELINE OVERVIEW
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
CONTACT | REDHILL
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites").CAREERS - HOME
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
COMMERCIAL PRODUCTS
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force. RedHill has assembled an experienced specialty GI commercial team, with a proven track-record, to lead its U.S. commercial operations. REDHILL BIOPHARMA COMPLETES ENROLLMENT OF ORAL OPAGANIB 1 Opaganib is an investigational new drug, not available for commercial distribution.. 2 Based on preliminary blinded blended data from 463 patients. The Company did not conduct a head-to-head comparison study in the same patient population. The theoretical comparison between the global Phase 2/3 study with opaganib and reported rates of mortality from large platform studies such asCROHN'S DISEASE
RedHill Presentation - International Research Symposium for Game Changing Concepts in Crohn’s Medicine (RHB-104 Phase III Program) RedHill Article (RHB-104) - Crohn's & Colitis Canada 2015 Gala Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Elaboration on Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Doctors have potentially found RHB-104 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHEUMATOID ARTHRITIS 20 May, 2021 RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021 ; 9 April, 2021 RedHill Biopharma’s Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue ; 25 March, 2021 RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PRODUCTS & PIPELINE
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PATIENT ASSISTANCE PROGRAM 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
CAREERS - HOME
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILLRHB 104 APPROVALRHB 104 NEWSRHB 104 RESULTSRHB 104 STUDY RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. CONTACT | REDHILLSEE MORE ON REDHILLBIO.COMCROHN'S DISEASE
RedHill Presentation - International Research Symposium for Game Changing Concepts in Crohn’s Medicine (RHB-104 Phase III Program) RedHill Article (RHB-104) - Crohn's & Colitis Canada 2015 Gala Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Elaboration on Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Doctors have potentially found HOME | REDHILLINVESTORSABOUT REDHILLPRODUCTSCOVID-19NEWSCONTACT 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PRODUCTS & PIPELINE
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PATIENT ASSISTANCE PROGRAM 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-107 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-107 (INN: upamostat) (formerly MESUPRON) is a proprietary, first-in-class orally-administered potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.. RHB-107 is being evaluated in a U.S. Phase 2/3 study for treatment in non-hospitalized patients with symptomatic COVID-19 who do not requireOPAGANIB (YELIVA®)
Opaganib (Yeliva ®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications.Opaganib is also under development as a potential therapy for COVID-19. INVESTORS | REDHILL BIOPHARMA LTD. The Investor Relations website contains information about RedHill Biopharma Ltd.'s business for stockholders, potential investors, andfinancial analysts.
CAREERS - HOME
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
RHB-204 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILLRHB 104 APPROVALRHB 104 NEWSRHB 104 RESULTSRHB 104 STUDY RHB-204 is a proprietary and innovative investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. CONTACT | REDHILLSEE MORE ON REDHILLBIO.COMCROHN'S DISEASE
RedHill Presentation - International Research Symposium for Game Changing Concepts in Crohn’s Medicine (RHB-104 Phase III Program) RedHill Article (RHB-104) - Crohn's & Colitis Canada 2015 Gala Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Elaboration on Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Doctors have potentially foundABOUT REDHILL
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
2020 | NEWS | REDHILL 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
PIPELINE OVERVIEW
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
CONTACT | REDHILL
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites").CAREERS - HOME
27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights ; 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 ; 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW2021
COMMERCIAL PRODUCTS
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force. RedHill has assembled an experienced specialty GI commercial team, with a proven track-record, to lead its U.S. commercial operations. REDHILL BIOPHARMA COMPLETES ENROLLMENT OF ORAL OPAGANIB 1 Opaganib is an investigational new drug, not available for commercial distribution.. 2 Based on preliminary blinded blended data from 463 patients. The Company did not conduct a head-to-head comparison study in the same patient population. The theoretical comparison between the global Phase 2/3 study with opaganib and reported rates of mortality from large platform studies such asCROHN'S DISEASE
RedHill Presentation - International Research Symposium for Game Changing Concepts in Crohn’s Medicine (RHB-104 Phase III Program) RedHill Article (RHB-104) - Crohn's & Colitis Canada 2015 Gala Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Elaboration on Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's Disease Doctors have potentially found RHB-104 | DEVELOPMENT PIPELINE | PRODUCTS | REDHILL RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHEUMATOID ARTHRITIS 20 May, 2021 RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021 ; 9 April, 2021 RedHill Biopharma’s Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue ; 25 March, 2021 RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSNMenu
* About RedHill
* Company Profile
* Senior Leadership
* Board of Directors* Advisory Board
* Partnering
* Products
* Commercial Products* Movantik®
* Talicia®
* Aemcolo®
* Development Pipeline* Pipeline Overview
* RHB-204
* RHB-104
* Crohn's disease
* Multiple Sclerosis * RHB-102 (Bekinda®) * Gastroenteritis & Gastritis* IBS-D
* RHB-106
* Opaganib (Yeliva®) * Opaganib - COVID-19* RHB-107
* Expanded Access Policy * PATIENT ASSISTANCE PROGRAM* COVID-19
* Investors
* News
* 2021
* 2020
* 2019
* 2018
* 2017
* 2016
* 2015
* 2014
* 2013
* Contact
* Partnering
* CAREERS
PIPELINE OVERVIEW*
PRODUCT1
INDICATION
PRE-CLINICAL
PHASE 1/2
PHASE 3
COMMERCIAL
Talicia®
_H. pylori_ infection2 APPROVED BY U.S. FDA NOVEMBER 2019MOVANTIK®
Opioid induced constipation3 GLOBAL RIGHTS EXCLUDING EUROPE, CANADA, ISRAELAemcolo®
Travelers' Diarrhea4 U.S. EXCLUSIVE LICENSEDonnatal®
IBS and acute enterocolitis5U.S. CO-PROMOTION
Mytesi®
Non-infectious diarrhea in HIV/AIDS patients5U.S. CO-PROMOTION
EnteraGam®
Chronic diarrhea and loose stools7 U.S. EXCLUSIVE LICENSE Esomeprazole Strontium DR Capsules GERD and other GI conditions6 U.S. COMMERCIALIZATION LICENSERHB-204
NTM infections
RHB-104
Crohn's disease
RHB-102
(Bekinda®)
Gastroenteritis & gastritisIBS-D
RHB-106
Bowel cleanser
Opaganib
(Yeliva®)
Oncology indications and COVID-19RHB-107
upamostat
Oncology/GI and COVID-19Other RIZAPORT®
(RHB-103)
Migraine
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies 1 Bekinda® (RHB-102) and Yeliva® (Opaganib) are proposed tradenames which are subject to FDA review and approval. 2 Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of _H. pylori_ infection in adults. For full prescribing information see: here 3 Movantik® (naloxegol) is indicated for the treatment of opioid induced constipation (OIC) in adults with chronic non cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation. For full prescribing information see: here 4 Aemcolo® (rifamycin) is indicated for the treatment of travelers diarrhea caused by noninvasive strains of _Escherichia Coli _ in adults. For full prescribing information see: hereCOMPANY PROFILE
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectiousdiseases.
Read more
RECENT NEWS
* 27 May, 2021 RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights * 26 May, 2021 RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 * 24 May, 2021 RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021SEE ALL NEWS
Home | Site Map
Copyright © 2017-2020. RedHill Biopharma Ltd. All Rights Reserved. Created by Catom web design | SEO Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. Ok Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. OkDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0